- Home
- IMTX vs BCAX Comparison
IMTX vs BCAX Comparison
Compare IMTX & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTX
- BCAX
- Stock Information
- Founded
- IMTX N/A
- BCAX 2018
- Country
- IMTX Germany
- BCAX United States
- Employees
- IMTX N/A
- BCAX N/A
- Industry
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- BCAX
- Sector
- IMTX Health Care
- BCAX
- Exchange
- IMTX Nasdaq
- BCAX NYSE
- Market Cap
- IMTX 653.9M
- BCAX 541.0M
- IPO Year
- IMTX N/A
- BCAX 2024
- Fundamental
- Price
- IMTX $6.56
- BCAX $11.75
- Analyst Decision
- IMTX Strong Buy
- BCAX Strong Buy
- Analyst Count
- IMTX 4
- BCAX 7
- Target Price
- IMTX $14.67
- BCAX $29.17
- AVG Volume (30 Days)
- IMTX 405.6K
- BCAX 533.0K
- Earning Date
- IMTX 08-12-2025
- BCAX 08-16-2025
- Dividend Yield
- IMTX N/A
- BCAX N/A
- EPS Growth
- IMTX N/A
- BCAX N/A
- EPS
- IMTX N/A
- BCAX N/A
- Revenue
- IMTX $155,801,989.00
- BCAX N/A
- Revenue This Year
- IMTX N/A
- BCAX N/A
- Revenue Next Year
- IMTX $1.92
- BCAX N/A
- P/E Ratio
- IMTX N/A
- BCAX N/A
- Revenue Growth
- IMTX 93.56
- BCAX N/A
- 52 Week Low
- IMTX $3.30
- BCAX $7.80
- 52 Week High
- IMTX $13.09
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- IMTX 66.69
- BCAX N/A
- Support Level
- IMTX $5.70
- BCAX N/A
- Resistance Level
- IMTX $6.57
- BCAX N/A
- Average True Range (ATR)
- IMTX 0.33
- BCAX 0.00
- MACD
- IMTX 0.05
- BCAX 0.00
- Stochastic Oscillator
- IMTX 99.50
- BCAX 0.00
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.